FDA Grants Fast Track Designation to CTX-009 in Biliary Tract Cancer

The combination of bispecific antibody CTX-009 and chemotherapy received Fast Track Designation for advanced, previously treated biliary tract cancers.

Related Keywords

Thomas Schuetz ,Drug Administration ,Compass Therapeutics Inc ,Fast Track ,Fast Track Designation ,Compass Therapeutics ,Track Designation ,Clinical Oncology ,Biliary Tract Cancer ,Fda Fast Track Designation ,